Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
April 11, 2019 09:27 ET
|
Altimmune, Inc.
GAITHERSBURG, Md., April 11, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress...
Verslo klientų vadovas Mindaugas Ubartas palieka „Telia Lietuva“ nuo 2019 m. balandžio 12 d.
March 21, 2019 03:30 ET
|
Telia Lietuva, AB
Telia Lietuva, AB (toliau – „Telia Lietuva“ arba Bendrovė) Verslo klientų vadovas Mindaugas Ubartas, taip pat laikinai einantis Privačių klientų vadovo pareigas, nusprendė palikti Bendrovę nuo 2019 m....
Mindaugas Ubartas, Head of Business to Business, to leave Telia Lietuva from 12 April, 2019
March 21, 2019 03:30 ET
|
Telia Lietuva
Head of Business to Business (B2B) and acting Head of Business to Consumer (B2C) at Telia Lietuva, AB (hereinafter – ‘Telia Lietuva’ or ‘the Company’) Mindaugas Ubartas decided to leave the Company...
Rapid7 Announces Fourth Quarter and Full-Year 2018 Financial Results
February 07, 2019 16:05 ET
|
Rapid7
Fourth quarter 2018 total revenue of $68.8 million and full year 2018 revenue of $244.1 million (under ASC 606)Fourth quarter 2018 revenue growth of 22% and full-year 2018 revenue growth of 27% (under...
Rapid7 Announces Third Quarter 2018 Financial Results
November 06, 2018 16:05 ET
|
Rapid7
Revenue of $62.4 million under ASC 606Revenue growth of 30% year-over-year under ASC 605Annualized recurring revenue of $217.4 million, an increase of 46% year-over-yearRaised revenue guidance for...
Rapid7 Acquires Leading Web Application Security Provider, tCell
October 15, 2018 16:30 ET
|
Rapid7
BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), powering SecOps through its visibility, analytics and automation cloud, today announced it acquired tCell.io, Inc., a leading...
T-Cell Immunotherapy Market, 2030 - Focus on CAR-T Therapies, TCR Therapies and TIL Therapies
September 19, 2018 06:55 ET
|
Research and Markets
Dublin, Sept. 19, 2018 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering. The "T-Cell...
T-Cell Immunotherapy Market, 2030 - Competitive Landscape Features a Mix of Established Players and Start-ups, with Academic Institutes Spearheading Early-stage Development Activities
June 08, 2018 10:00 ET
|
Research and Markets
Dublin, June 08, 2018 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market (3rd Edition), 2018-2030" report has been added to ResearchAndMarkets.com's offering. The "T-Cell...
T-Cell Immunotherapy Market for Cancer & Pipeline Analysis Report 2018
April 13, 2018 05:08 ET
|
Research and Markets
Dublin, April 13, 2018 (GLOBE NEWSWIRE) -- The "Global T-Cell Immunotherapy Market for Cancer & Pipeline Analysis " report has been added to ResearchAndMarkets.com's offering. ...
Allegis Capital Adds Dave DeWalt—Former FireEye CEO—To Partnership as Managing Director; Firm Also Announces Name Change to AllegisCyber, Reflecting an Expanded Seed to Growth Stage Strategy; AllegisCyber will actively expand its cyber investments on the East coast
October 26, 2017 10:00 ET
|
Allegis Capital
SAN FRANCISCO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Allegis Capital, an early-stage cybersecurity venture capital firm, announced today that David G. DeWalt, the previous CEO of publicly held FireEye...